Search Results for: Cancer

23406 interactions found:

Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
CALM1 and DAPK1 calmodulin 1 (phosphorylase kinase, delta) death-associated protein kinase 1
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Ca-dependent events
  • CaM pathway
  • Signaling by FGFR in disease
  • Phospholipase C-mediated cascade
  • Signaling by Wnt
  • Platelet degranulation
  • Signaling by EGFRvIII in Cancer
  • CREB phosphorylation through the activation of Ras
  • PLCG1 events in ERBB2 signaling
  • Glucose metabolism
  • DAP12 signaling
  • Synthesis of IP3 and IP4 in the cytosol
  • Myoclonic epilepsy of Lafora
  • Response to elevated platelet cytosolic Ca2+
  • Glycogen storage diseases
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Activation of Ca-permeable Kainate Receptor
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Ionotropic activity of Kainate Receptors
  • Signaling by PDGF
  • Calmodulin induced events
  • CaMK IV-mediated phosphorylation of CREB
  • DAP12 interactions
  • Glycogen breakdown (glycogenolysis)
  • Opioid Signalling
  • Activation of Kainate Receptors upon glutamate binding
  • Diseases associated with visual transduction
  • Inositol phosphate metabolism
  • EGFR interacts with phospholipase C-gamma
  • CaMK IV-mediated phosphorylation of CREB
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by VEGF
  • CREB phosphorylation through the activation of CaMKK
  • Downstream signal transduction
  • Calmodulin induced events
  • CREB phosphorylation through the activation of CaMKII
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Transcriptional activation of mitochondrial biogenesis
  • Metabolism of carbohydrates
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Organelle biogenesis and maintenance
  • Cam-PDE 1 activation
  • Translocation of GLUT4 to the plasma membrane
  • VEGFA-VEGFR2 Pathway
  • DAG and IP3 signaling
  • CaM pathway
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Metabolism of nitric oxide
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated vascular permeability
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • The phototransduction cascade
  • Downstream signaling of activated FGFR
  • DARPP-32 events
  • eNOS activation and regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Post NMDA receptor activation events
  • Signalling by NGF
  • PLC beta mediated events
  • Smooth Muscle Contraction
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Mitochondrial biogenesis
  • beta-catenin independent WNT signaling
  • Signaling by FGFR
  • eNOS activation
  • Cam-PDE 1 activation
  • Ca2+ pathway
  • Visual phototransduction
  • Activation of CaMK IV
  • PLC-gamma1 signalling
  • FCERI mediated Ca+2 mobilization
  • Programmed Cell Death
  • Role of DCC in regulating apoptosis
  • Extrinsic Pathway
  • 5,6-Dihydro-Benzo[H]Cinnolin-3-Ylamine
  • Phosphoaminophosphonic Acid-Adenylate Ester
  • 6-(3-AMINOPROPYL)-4,9-DIMETHYLPYRROLO[3,4-C]CARBAZOLE-1,3(2H,6H)-DIONE
CALM2 and EGFR calmodulin 2 (phosphorylase kinase, delta) epidermal growth factor receptor
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Ca-dependent events
  • CaM pathway
  • Signaling by FGFR in disease
  • Phospholipase C-mediated cascade
  • Signaling by Wnt
  • Platelet degranulation
  • Signaling by EGFRvIII in Cancer
  • CREB phosphorylation through the activation of Ras
  • PLCG1 events in ERBB2 signaling
  • Glucose metabolism
  • DAP12 signaling
  • Synthesis of IP3 and IP4 in the cytosol
  • Myoclonic epilepsy of Lafora
  • Response to elevated platelet cytosolic Ca2+
  • Glycogen storage diseases
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Activation of Ca-permeable Kainate Receptor
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Ionotropic activity of Kainate Receptors
  • Signaling by PDGF
  • Calmodulin induced events
  • CaMK IV-mediated phosphorylation of CREB
  • DAP12 interactions
  • Glycogen breakdown (glycogenolysis)
  • Opioid Signalling
  • Activation of Kainate Receptors upon glutamate binding
  • Diseases associated with visual transduction
  • Inositol phosphate metabolism
  • EGFR interacts with phospholipase C-gamma
  • CaMK IV-mediated phosphorylation of CREB
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by VEGF
  • CREB phosphorylation through the activation of CaMKK
  • Downstream signal transduction
  • Calmodulin induced events
  • CREB phosphorylation through the activation of CaMKII
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Transcriptional activation of mitochondrial biogenesis
  • Metabolism of carbohydrates
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Organelle biogenesis and maintenance
  • Cam-PDE 1 activation
  • Translocation of GLUT4 to the plasma membrane
  • VEGFA-VEGFR2 Pathway
  • DAG and IP3 signaling
  • CaM pathway
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Metabolism of nitric oxide
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated vascular permeability
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • The phototransduction cascade
  • Downstream signaling of activated FGFR
  • DARPP-32 events
  • eNOS activation and regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Post NMDA receptor activation events
  • Signalling by NGF
  • PLC beta mediated events
  • Smooth Muscle Contraction
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Mitochondrial biogenesis
  • beta-catenin independent WNT signaling
  • Signaling by FGFR
  • eNOS activation
  • Cam-PDE 1 activation
  • Ca2+ pathway
  • Visual phototransduction
  • Activation of CaMK IV
  • PLC-gamma1 signalling
  • FCERI mediated Ca+2 mobilization
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
CALM2 and CCND2 calmodulin 2 (phosphorylase kinase, delta) cyclin D2
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Ca-dependent events
  • CaM pathway
  • Signaling by FGFR in disease
  • Phospholipase C-mediated cascade
  • Signaling by Wnt
  • Platelet degranulation
  • Signaling by EGFRvIII in Cancer
  • CREB phosphorylation through the activation of Ras
  • PLCG1 events in ERBB2 signaling
  • Glucose metabolism
  • DAP12 signaling
  • Synthesis of IP3 and IP4 in the cytosol
  • Myoclonic epilepsy of Lafora
  • Response to elevated platelet cytosolic Ca2+
  • Glycogen storage diseases
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Activation of Ca-permeable Kainate Receptor
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Ionotropic activity of Kainate Receptors
  • Signaling by PDGF
  • Calmodulin induced events
  • CaMK IV-mediated phosphorylation of CREB
  • DAP12 interactions
  • Glycogen breakdown (glycogenolysis)
  • Opioid Signalling
  • Activation of Kainate Receptors upon glutamate binding
  • Diseases associated with visual transduction
  • Inositol phosphate metabolism
  • EGFR interacts with phospholipase C-gamma
  • CaMK IV-mediated phosphorylation of CREB
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by VEGF
  • CREB phosphorylation through the activation of CaMKK
  • Downstream signal transduction
  • Calmodulin induced events
  • CREB phosphorylation through the activation of CaMKII
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Transcriptional activation of mitochondrial biogenesis
  • Metabolism of carbohydrates
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Organelle biogenesis and maintenance
  • Cam-PDE 1 activation
  • Translocation of GLUT4 to the plasma membrane
  • VEGFA-VEGFR2 Pathway
  • DAG and IP3 signaling
  • CaM pathway
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Metabolism of nitric oxide
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated vascular permeability
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • The phototransduction cascade
  • Downstream signaling of activated FGFR
  • DARPP-32 events
  • eNOS activation and regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Post NMDA receptor activation events
  • Signalling by NGF
  • PLC beta mediated events
  • Smooth Muscle Contraction
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Mitochondrial biogenesis
  • beta-catenin independent WNT signaling
  • Signaling by FGFR
  • eNOS activation
  • Cam-PDE 1 activation
  • Ca2+ pathway
  • Visual phototransduction
  • Activation of CaMK IV
  • PLC-gamma1 signalling
  • FCERI mediated Ca+2 mobilization
  • Cyclin D associated events in G1
  • G1 Phase
  • Mitotic G1-G1/S phases
  • Cell Cycle, Mitotic
CALM3 and EGFR calmodulin 3 (phosphorylase kinase, delta) epidermal growth factor receptor
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Ca-dependent events
  • CaM pathway
  • Signaling by FGFR in disease
  • Phospholipase C-mediated cascade
  • Signaling by Wnt
  • Platelet degranulation
  • Signaling by EGFRvIII in Cancer
  • CREB phosphorylation through the activation of Ras
  • PLCG1 events in ERBB2 signaling
  • Glucose metabolism
  • DAP12 signaling
  • Synthesis of IP3 and IP4 in the cytosol
  • Myoclonic epilepsy of Lafora
  • Response to elevated platelet cytosolic Ca2+
  • Glycogen storage diseases
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Activation of Ca-permeable Kainate Receptor
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Ionotropic activity of Kainate Receptors
  • Signaling by PDGF
  • Calmodulin induced events
  • CaMK IV-mediated phosphorylation of CREB
  • DAP12 interactions
  • Glycogen breakdown (glycogenolysis)
  • Opioid Signalling
  • Activation of Kainate Receptors upon glutamate binding
  • Diseases associated with visual transduction
  • Inositol phosphate metabolism
  • EGFR interacts with phospholipase C-gamma
  • CaMK IV-mediated phosphorylation of CREB
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by VEGF
  • CREB phosphorylation through the activation of CaMKK
  • Downstream signal transduction
  • Calmodulin induced events
  • CREB phosphorylation through the activation of CaMKII
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Transcriptional activation of mitochondrial biogenesis
  • Metabolism of carbohydrates
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Organelle biogenesis and maintenance
  • Cam-PDE 1 activation
  • Translocation of GLUT4 to the plasma membrane
  • VEGFA-VEGFR2 Pathway
  • DAG and IP3 signaling
  • CaM pathway
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Metabolism of nitric oxide
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated vascular permeability
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • The phototransduction cascade
  • Downstream signaling of activated FGFR
  • DARPP-32 events
  • eNOS activation and regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Post NMDA receptor activation events
  • Signalling by NGF
  • PLC beta mediated events
  • Smooth Muscle Contraction
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Mitochondrial biogenesis
  • beta-catenin independent WNT signaling
  • Signaling by FGFR
  • eNOS activation
  • Cam-PDE 1 activation
  • Ca2+ pathway
  • Visual phototransduction
  • Activation of CaMK IV
  • PLC-gamma1 signalling
  • FCERI mediated Ca+2 mobilization
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Dibucaine
  • Nicardipine
  • Fluphenazine
  • Isoflurane
  • Trifluoperazine
  • Loperamide
  • Perphenazine
  • Phenoxybenzamine
  • Felodipine
  • Melatonin
  • Promethazine
  • Pimozide
  • Nifedipine
  • Bepridil
  • Calcium
  • Aprindine
  • 3\'\'-(Beta-Chloroethyl)-2\'\',4\'\'-Dioxo-3, 5\'\'-Spiro-Oxazolidino-4-Deacetoxy-Vinblastine
  • 2-Methyl-2-Propanol
  • N-Trimethyllysine
  • N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide
  • Prenylamine
  • Flunarizine
  • (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE
  • MYRISTIC ACID
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
CALM3 and CCND2 calmodulin 3 (phosphorylase kinase, delta) cyclin D2
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Ca-dependent events
  • CaM pathway
  • Signaling by FGFR in disease
  • Phospholipase C-mediated cascade
  • Signaling by Wnt
  • Platelet degranulation
  • Signaling by EGFRvIII in Cancer
  • CREB phosphorylation through the activation of Ras
  • PLCG1 events in ERBB2 signaling
  • Glucose metabolism
  • DAP12 signaling
  • Synthesis of IP3 and IP4 in the cytosol
  • Myoclonic epilepsy of Lafora
  • Response to elevated platelet cytosolic Ca2+
  • Glycogen storage diseases
  • Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation
  • Activation of Ca-permeable Kainate Receptor
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • Ionotropic activity of Kainate Receptors
  • Signaling by PDGF
  • Calmodulin induced events
  • CaMK IV-mediated phosphorylation of CREB
  • DAP12 interactions
  • Glycogen breakdown (glycogenolysis)
  • Opioid Signalling
  • Activation of Kainate Receptors upon glutamate binding
  • Diseases associated with visual transduction
  • Inositol phosphate metabolism
  • EGFR interacts with phospholipase C-gamma
  • CaMK IV-mediated phosphorylation of CREB
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by VEGF
  • CREB phosphorylation through the activation of CaMKK
  • Downstream signal transduction
  • Calmodulin induced events
  • CREB phosphorylation through the activation of CaMKII
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • Transcriptional activation of mitochondrial biogenesis
  • Metabolism of carbohydrates
  • Platelet activation, signaling and aggregation
  • Adaptive Immune System
  • Transmission across Chemical Synapses
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Organelle biogenesis and maintenance
  • Cam-PDE 1 activation
  • Translocation of GLUT4 to the plasma membrane
  • VEGFA-VEGFR2 Pathway
  • DAG and IP3 signaling
  • CaM pathway
  • Inactivation, recovery and regulation of the phototransduction cascade
  • Metabolism of nitric oxide
  • VEGFR2 mediated cell proliferation
  • VEGFR2 mediated vascular permeability
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • The phototransduction cascade
  • Downstream signaling of activated FGFR
  • DARPP-32 events
  • eNOS activation and regulation
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Innate Immune System
  • Post NMDA receptor activation events
  • Signalling by NGF
  • PLC beta mediated events
  • Smooth Muscle Contraction
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • G-protein mediated events
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Mitochondrial biogenesis
  • beta-catenin independent WNT signaling
  • Signaling by FGFR
  • eNOS activation
  • Cam-PDE 1 activation
  • Ca2+ pathway
  • Visual phototransduction
  • Activation of CaMK IV
  • PLC-gamma1 signalling
  • FCERI mediated Ca+2 mobilization
  • Cyclin D associated events in G1
  • G1 Phase
  • Mitotic G1-G1/S phases
  • Cell Cycle, Mitotic
  • Dibucaine
  • Nicardipine
  • Fluphenazine
  • Isoflurane
  • Trifluoperazine
  • Loperamide
  • Perphenazine
  • Phenoxybenzamine
  • Felodipine
  • Melatonin
  • Promethazine
  • Pimozide
  • Nifedipine
  • Bepridil
  • Calcium
  • Aprindine
  • 3\'\'-(Beta-Chloroethyl)-2\'\',4\'\'-Dioxo-3, 5\'\'-Spiro-Oxazolidino-4-Deacetoxy-Vinblastine
  • 2-Methyl-2-Propanol
  • N-Trimethyllysine
  • N-(6-Aminohexyl)-5-Chloro-1-Naphthalenesulfonamide
  • Prenylamine
  • Flunarizine
  • (3Z)-N,N-DIMETHYL-2-OXO-3-(4,5,6,7-TETRAHYDRO-1H-INDOL-2-YLMETHYLIDENE)-2,3-DIHYDRO-1H-INDOLE-5-SULFONAMIDE
  • MYRISTIC ACID
CASP3 and CDKN1A caspase 3, apoptosis-related cysteine peptidase cyclin-dependent kinase inhibitor 1A (p21, Cip1)
  • SMAC binds to IAPs
  • SMAC-mediated dissociation of IAP:caspase complexes
  • SMAC-mediated apoptotic response
  • Cytochrome c-mediated apoptotic response
  • Caspase-mediated cleavage of cytoskeletal proteins
  • Degradation of the extracellular matrix
  • Role of DCC in regulating apoptosis
  • Activation of caspases through apoptosome-mediated cleavage
  • Activation of DNA fragmentation factor
  • Apoptotic factor-mediated response
  • Programmed Cell Death
  • Intrinsic Pathway for Apoptosis
  • Signalling by NGF
  • Apoptotic cleavage of cellular proteins
  • Cell death signalling via NRAGE, NRIF and NADE
  • Apoptotic execution phase
  • p75 NTR receptor-mediated signalling
  • Stimulation of the cell death response by PAK-2p34
  • Apoptotic cleavage of cell adhesion proteins
  • Signaling by Hippo
  • Apoptosis induced DNA fragmentation
  • Extrinsic Pathway
  • NADE modulates death signalling
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Cellular Senescence
  • p53-Dependent G1/S DNA damage checkpoint
  • Cyclin E associated events during G1/S transition
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • G1/S Transition
  • Removal of licensing factors from origins
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • Signaling by PDGF
  • DAP12 interactions
  • DNA Damage/Telomere Stress Induced Senescence
  • GAB1 signalosome
  • Senescence-Associated Secretory Phenotype (SASP)
  • S Phase
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • SCF(Skp2)-mediated degradation of p27/p21
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Adaptive Immune System
  • PIP3 activates AKT signaling
  • Orc1 removal from chromatin
  • p53-Dependent G1 DNA Damage Response
  • PI3K events in ERBB2 signaling
  • Transcriptional activation of p53 responsive genes
  • Downstream signaling of activated FGFR
  • G1/S DNA Damage Checkpoints
  • Innate Immune System
  • Transcriptional activation of cell cycle inhibitor p21
  • Signalling by NGF
  • Synthesis of DNA
  • G1 Phase
  • Regulation of DNA replication
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell Cycle, Mitotic
  • Signaling by FGFR
  • Orc1 removal from chromatin
  • Cyclin D associated events in G1
  • Cell Cycle Checkpoints
  • Minocycline
  • 5-[4-(1-Carboxymethyl-2-Oxo-Propylcarbamoyl)-Benzylsulfamoyl]-2-Hydroxy-Benzoic Acid
  • 2-HYDROXY-5-(2-MERCAPTO-ETHYLSULFAMOYL)-BENZOIC ACID
  • methyl (3S)-3-[(tert-butoxycarbonyl)amino]-4-oxopentanoate
  • 1-METHYL-5-(2-PHENOXYMETHYL-PYRROLIDINE-1-SULFONYL)-1H-INDOLE-2,3-DIONE
  • [N-(3-DIBENZYLCARBAMOYL-OXIRANECARBONYL)-HYDRAZINO]-ACETIC ACID
  • 4-[5-(2-CARBOXY-1-FORMYL-ETHYLCARBAMOYL)-PYRIDIN-3-YL]-BENZOIC ACID
  • (1S)-2-oxo-1-phenyl-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
  • (1S)-1-(3-chlorophenyl)-2-oxo-2-[(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-5-yl)amino]ethyl acetate
  • N-[3-(2-fluoroethoxy)phenyl]-N\'-(1,3,4-trioxo-1,2,3,4-tetrahydroisoquinolin-6-yl)butanediamide
CASP9 and DCC caspase 9, apoptosis-related cysteine peptidase DCC netrin 1 receptor
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • SMAC binds to IAPs
  • SMAC-mediated dissociation of IAP:caspase complexes
  • Cytochrome c-mediated apoptotic response
  • SMAC-mediated apoptotic response
  • Signaling by EGFRvIII in Cancer
  • AKT phosphorylates targets in the cytosol
  • Role of DCC in regulating apoptosis
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Activation of caspases through apoptosome-mediated cleavage
  • Formation of apoptosome
  • PI3K/AKT activation
  • PI-3K cascade
  • Apoptotic factor-mediated response
  • NOD1/2 Signaling Pathway
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Programmed Cell Death
  • Innate Immune System
  • Intrinsic Pathway for Apoptosis
  • Signaling by PDGF
  • DAP12 interactions
  • Signalling by NGF
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Extrinsic Pathway
  • Adaptive Immune System
  • DSCAM interactions
  • Axon guidance
  • Role of second messengers in netrin-1 signaling
  • DCC mediated attractive signaling
  • Programmed Cell Death
  • Netrin mediated repulsion signals
  • Netrin-1 signaling
  • Role of DCC in regulating apoptosis
  • Extrinsic Pathway
CAV1 and ERBB2 caveolin 1, caveolae protein, 22kDa erb-b2 receptor tyrosine kinase 2
  • Metabolism of lipids and lipoproteins
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Lipid digestion, mobilization, and transport
  • Signaling by Wnt
  • Basigin interactions
  • VEGFA-VEGFR2 Pathway
  • Cell surface interactions at the vascular wall
  • eNOS activation
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Metabolism of nitric oxide
  • Signaling by VEGF
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
  • NOSTRIN mediated eNOS trafficking
  • VEGFR2 mediated vascular permeability
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • eNOS activation and regulation
  • Signaling by WNT in cancer
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Axon guidance
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Sema4D in semaphorin signaling
  • Sema4D induced cell migration and growth-cone collapse
  • Innate Immune System
  • Signaling by PDGF
  • Downregulation of ERBB2:ERBB3 signaling
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Trastuzumab
  • Lapatinib
  • ado-trastuzumab emtansine
  • Pertuzumab
  • Afatinib
CAV1 and PTEN caveolin 1, caveolae protein, 22kDa phosphatase and tensin homolog
  • Metabolism of lipids and lipoproteins
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Lipid digestion, mobilization, and transport
  • Signaling by Wnt
  • Basigin interactions
  • VEGFA-VEGFR2 Pathway
  • Cell surface interactions at the vascular wall
  • eNOS activation
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Metabolism of nitric oxide
  • Signaling by VEGF
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
  • NOSTRIN mediated eNOS trafficking
  • VEGFR2 mediated vascular permeability
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • eNOS activation and regulation
  • Signaling by WNT in cancer
  • Signaling by the B Cell Receptor (BCR)
  • Downstream TCR signaling
  • Metabolism of lipids and lipoproteins
  • Signaling by FGFR in disease
  • PIP3 activates AKT signaling
  • Signaling by EGFRvIII in Cancer
  • Synthesis of PIPs at the plasma membrane
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • PI3K/AKT activation
  • Synthesis of IP3 and IP4 in the cytosol
  • PI-3K cascade
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Phospholipid metabolism
  • PI Metabolism
  • Innate Immune System
  • Signaling by PDGF
  • DAP12 interactions
  • Signalling by NGF
  • GAB1 signalosome
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Negative regulation of the PI3K/AKT network
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Inositol phosphate metabolism
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • TCR signaling
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
CAV1 and HRAS caveolin 1, caveolae protein, 22kDa Harvey rat sarcoma viral oncogene homolog
  • Metabolism of lipids and lipoproteins
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Lipid digestion, mobilization, and transport
  • Signaling by Wnt
  • Basigin interactions
  • VEGFA-VEGFR2 Pathway
  • Cell surface interactions at the vascular wall
  • eNOS activation
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Metabolism of nitric oxide
  • Signaling by VEGF
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
  • NOSTRIN mediated eNOS trafficking
  • VEGFR2 mediated vascular permeability
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • eNOS activation and regulation
  • Signaling by WNT in cancer
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • SHC-mediated cascade
  • MEK activation
  • FCERI mediated MAPK activation
  • CREB phosphorylation through the activation of Ras
  • Signaling by EGFRvIII in Cancer
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Interleukin receptor SHC signaling
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • p38MAPK events
  • EPH-Ephrin signaling
  • SOS-mediated signalling
  • Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
  • SHC-mediated signalling
  • Signaling by PDGF
  • DAP12 interactions
  • SHC-related events triggered by IGF1R
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • SHC1 events in ERBB4 signaling
  • Signaling by VEGF
  • Signalling to RAS
  • Downstream signal transduction
  • Signaling by FGFR mutants
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • Interleukin-2 signaling
  • Interleukin-3, 5 and GM-CSF signaling
  • Frs2-mediated activation
  • Transmission across Chemical Synapses
  • Ras activation uopn Ca2+ infux through NMDA receptor
  • Adaptive Immune System
  • Signaling by Leptin
  • Signalling to ERKs
  • Prolonged ERK activation events
  • Axon guidance
  • IRS-mediated signalling
  • IGF1R signaling cascade
  • VEGFA-VEGFR2 Pathway
  • EPHB-mediated forward signaling
  • IRS-related events triggered by IGF1R
  • EGFR Transactivation by Gastrin
  • VEGFR2 mediated cell proliferation
  • GRB2 events in ERBB2 signaling
  • Activation of NMDA receptor upon glutamate binding and postsynaptic events
  • RAF phosphorylates MEK
  • Downstream signaling of activated FGFR
  • NCAM signaling for neurite out-growth
  • RAF/MAP kinase cascade
  • Signalling to p38 via RIT and RIN
  • Post NMDA receptor activation events
  • Innate Immune System
  • Signaling by Insulin receptor
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SOS-mediated signalling
  • SHC-mediated signalling
  • IRS-related events
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • SHC-related events
  • NGF signalling via TRKA from the plasma membrane
  • Tie2 Signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell surface interactions at the vascular wall
  • Signaling by FGFR
  • ARMS-mediated activation
  • SHC1 events in EGFR signaling
  • RAF activation
  • IRS-mediated signalling
  • FRS2-mediated cascade
  • Activation of RAS in B cells
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Interleukin receptor SHC signaling
  • Constitutive Signaling by EGFRvIII
  • Hexane-1,6-Diol
  • Trifluoroethanol
  • Guanosine-5\'-Triphosphate
  • Guanosine-5\'-Diphosphate
  • N,N\'-DIMETHYL-N-(ACETYL)-N\'-(7-NITROBENZ-2-OXA-1,3-DIAZOL-4-YL)ETHYLENEDIAMINE
CAV1 and EGFR caveolin 1, caveolae protein, 22kDa epidermal growth factor receptor
  • Metabolism of lipids and lipoproteins
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Lipid digestion, mobilization, and transport
  • Signaling by Wnt
  • Basigin interactions
  • VEGFA-VEGFR2 Pathway
  • Cell surface interactions at the vascular wall
  • eNOS activation
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • Metabolism of nitric oxide
  • Signaling by VEGF
  • TCF dependent signaling in response to WNT
  • RNF mutants show enhanced WNT signaling and proliferation
  • Hormone-sensitive lipase (HSL)-mediated triacylglycerol hydrolysis
  • NOSTRIN mediated eNOS trafficking
  • VEGFR2 mediated vascular permeability
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • eNOS activation and regulation
  • Signaling by WNT in cancer
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
RUNX1 and CCND2 runt-related transcription factor 1 cyclin D2
  • Cyclin D associated events in G1
  • G1 Phase
  • Mitotic G1-G1/S phases
  • Cell Cycle, Mitotic
RUNX1 and CTBP2 runt-related transcription factor 1 C-terminal binding protein 2
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • Signaling by Wnt
  • APC truncation mutants are not K63 polyubiquitinated
  • repression of WNT target genes
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • deletions in the AMER1 gene destabilize the destruction complex
  • AMER1 mutants destabilize the destruction complex
  • S33 mutants of beta-catenin aren't phosphorylated
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • truncations of AMER1 destabilize the destruction complex
CBL and ERBB2 Cbl proto-oncogene, E3 ubiquitin protein ligase erb-b2 receptor tyrosine kinase 2
  • Signaling by the B Cell Receptor (BCR)
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by FGFR in disease
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Interleukin-6 signaling
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Regulation of signaling by CBL
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Negative regulation of FGFR signaling
  • EGFR downregulation
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Spry regulation of FGF signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by FGFR
  • Signaling by EGFR
  • Signaling by Interleukins
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by EGFR in Cancer
  • Constitutive Signaling by EGFRvIII
  • Interleukin-3, 5 and GM-CSF signaling
  • SMAD4 MH2 Domain Mutants in Cancer
  • Adaptive Immune System
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Axon guidance
  • PIP3 activates AKT signaling
  • GRB7 events in ERBB2 signaling
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • SHC1 events in ERBB2 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Sema4D in semaphorin signaling
  • Sema4D induced cell migration and growth-cone collapse
  • Innate Immune System
  • Signaling by PDGF
  • Downregulation of ERBB2:ERBB3 signaling
  • Signalling by NGF
  • DAP12 interactions
  • GAB1 signalosome
  • Semaphorin interactions
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by ERBB4
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • Constitutive PI3K/AKT Signaling in Cancer
  • PI3K events in ERBB4 signaling
  • Signaling by FGFR
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Fc epsilon receptor (FCERI) signaling
  • Signaling by EGFR in Cancer
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Trastuzumab
  • Lapatinib
  • ado-trastuzumab emtansine
  • Pertuzumab
  • Afatinib
CBL and SHC1 Cbl proto-oncogene, E3 ubiquitin protein ligase SHC (Src homology 2 domain containing) transforming protein 1
  • Signaling by the B Cell Receptor (BCR)
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by FGFR in disease
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Interleukin-6 signaling
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Regulation of signaling by CBL
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Negative regulation of FGFR signaling
  • EGFR downregulation
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Spry regulation of FGF signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by FGFR
  • Signaling by EGFR
  • Signaling by Interleukins
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by EGFR in Cancer
  • Constitutive Signaling by EGFRvIII
  • Interleukin-3, 5 and GM-CSF signaling
  • SMAD4 MH2 Domain Mutants in Cancer
  • Adaptive Immune System
  • Signaling by GPCR
  • Signaling by EGFRvIII in Cancer
  • Platelet Aggregation (Plug Formation)
  • SHC1 events in ERBB2 signaling
  • IRE1alpha activates chaperones
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Interleukin receptor SHC signaling
  • SHC-mediated signalling
  • G-protein beta:gamma signalling
  • SHC-related events triggered by IGF1R
  • Signaling by ERBB4
  • Signaling by ERBB2
  • Signaling by EGFR
  • Signaling by Interleukins
  • GPCR downstream signaling
  • SHC1 events in ERBB4 signaling
  • Signalling to RAS
  • Signaling by EGFR in Cancer
  • Interleukin-2 signaling
  • Platelet activation, signaling and aggregation
  • Interleukin-3, 5 and GM-CSF signaling
  • Signalling to ERKs
  • IGF1R signaling cascade
  • XBP1(S) activates chaperone genes
  • G beta:gamma signalling through PI3Kgamma
  • Unfolded Protein Response (UPR)
  • Signaling by Insulin receptor
  • Signalling by NGF
  • Insulin receptor signalling cascade
  • SHC-mediated signalling
  • Integrin alphaIIb beta3 signaling
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Cytokine Signaling in Immune system
  • NGF signalling via TRKA from the plasma membrane
  • SHC-related events
  • Tie2 Signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell surface interactions at the vascular wall
  • SHC1 events in EGFR signaling
  • Signal attenuation
  • Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)
  • Interleukin receptor SHC signaling
  • GPVI-mediated activation cascade
  • Constitutive Signaling by EGFRvIII
  • SHC activation
CBL and EGFR Cbl proto-oncogene, E3 ubiquitin protein ligase epidermal growth factor receptor
  • Signaling by the B Cell Receptor (BCR)
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by FGFR in disease
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Interleukin-6 signaling
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Regulation of signaling by CBL
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Negative regulation of FGFR signaling
  • EGFR downregulation
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Spry regulation of FGF signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by FGFR
  • Signaling by EGFR
  • Signaling by Interleukins
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by EGFR in Cancer
  • Constitutive Signaling by EGFRvIII
  • Interleukin-3, 5 and GM-CSF signaling
  • SMAD4 MH2 Domain Mutants in Cancer
  • Adaptive Immune System
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by GPCR
  • Signaling by FGFR in disease
  • Signaling by EGFRvIII in Cancer
  • PLCG1 events in ERBB2 signaling
  • SHC1 events in ERBB2 signaling
  • Signaling by SCF-KIT
  • DAP12 signaling
  • Downstream signaling events of B Cell Receptor (BCR)
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • PI3K/AKT activation
  • PI-3K cascade
  • Gastrin-CREB signalling pathway via PKC and MAPK
  • Signaling by PDGF
  • EGFR downregulation
  • DAP12 interactions
  • GAB1 signalosome
  • GRB2 events in EGFR signaling
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • EGFR interacts with phospholipase C-gamma
  • Signaling by ERBB2
  • Signaling by EGFR
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Adaptive Immune System
  • Axon guidance
  • PIP3 activates AKT signaling
  • L1CAM interactions
  • EGFR Transactivation by Gastrin
  • GRB2 events in ERBB2 signaling
  • PI3K events in ERBB2 signaling
  • Downstream signaling of activated FGFR
  • Innate Immune System
  • Signalling by NGF
  • Signal transduction by L1
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Inhibition of Signaling by Overexpressed EGFR
  • Signaling by FGFR
  • SHC1 events in EGFR signaling
  • Constitutive Signaling by EGFRvIII
  • Cetuximab
  • Trastuzumab
  • Lidocaine
  • Gefitinib
  • Erlotinib
  • Lapatinib
  • Panitumumab
  • Flavopiridol
  • Vandetanib
  • S-{3-[(4-ANILINOQUINAZOLIN-6-YL)AMINO]-3-OXOPROPYL}-L-CYSTEINE
  • N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE
  • Afatinib
CBL and CTNNB1 Cbl proto-oncogene, E3 ubiquitin protein ligase catenin (cadherin-associated protein), beta 1, 88kDa
  • Signaling by the B Cell Receptor (BCR)
  • Loss of Function of TGFBR2 in Cancer
  • Signaling by FGFR in disease
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Interleukin-6 signaling
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Regulation of KIT signaling
  • Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants
  • Regulation of signaling by CBL
  • Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
  • Negative regulation of FGFR signaling
  • EGFR downregulation
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • Cytokine Signaling in Immune system
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • Spry regulation of FGF signaling
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by FGFR
  • Signaling by EGFR
  • Signaling by Interleukins
  • Signaling by TGF-beta Receptor Complex
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by EGFR in Cancer
  • Constitutive Signaling by EGFRvIII
  • Interleukin-3, 5 and GM-CSF signaling
  • SMAD4 MH2 Domain Mutants in Cancer
  • Adaptive Immune System
  • APC truncation mutants have impaired AXIN binding
  • misspliced GSK3beta mutants stabilize beta-catenin
  • T41 mutants of beta-catenin aren't phosphorylated
  • TCF7L2 mutants don't bind CTBP
  • truncated APC mutants destabilize the destruction complex
  • Signaling by Wnt
  • binding of TCF/LEF:CTNNB1 to target gene promoters
  • deactivation of the beta-catenin transactivating complex
  • APC truncation mutants are not K63 polyubiquitinated
  • disassembly of the destruction complex and recruitment of AXIN to the membrane
  • S37 mutants of beta-catenin aren't phosphorylated
  • Degradation of beta-catenin by the destruction complex
  • AXIN mutants destabilize the destruction complex, activating WNT signaling
  • RNF mutants show enhanced WNT signaling and proliferation
  • S33 mutants of beta-catenin aren't phosphorylated
  • XAV939 inhibits tankyrase, stabilizing AXIN
  • Innate Immune System
  • truncations of AMER1 destabilize the destruction complex
  • CDO in myogenesis
  • misspliced LRP5 mutants have enhanced beta-catenin-dependent signaling
  • Cytosolic sensors of pathogen-associated DNA
  • formation of the beta-catenin:TCF transactivating complex
  • phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex
  • AXIN missense mutants destabilize the destruction complex
  • S45 mutants of beta-catenin aren't phosphorylated
  • repression of WNT target genes
  • beta-catenin independent WNT signaling
  • deletions in the AMER1 gene destabilize the destruction complex
  • Ca2+ pathway
  • Myogenesis
  • AMER1 mutants destabilize the destruction complex
  • TCF dependent signaling in response to WNT
  • LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production
  • deletions in the AXIN genes in hepatocellular carcinoma result in elevated WNT signaling
  • Signaling by WNT in cancer
  • Urea
CCNA2 and CDKN1A cyclin A2 cyclin-dependent kinase inhibitor 1A (p21, Cip1)
  • Cellular Senescence
  • G2/M Transition
  • Orc1 removal from chromatin
  • Cyclin E associated events during G1/S transition
  • Cyclin A/B1 associated events during G2/M transition
  • G1/S Transition
  • G2 Phase
  • Removal of licensing factors from origins
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • DNA Damage/Telomere Stress Induced Senescence
  • Synthesis of DNA
  • Regulation of DNA replication
  • G0 and Early G1
  • Phosphorylation of proteins involved in the G2/M transition by Cyclin A:Cdc2 complexes
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Senescence-Associated Secretory Phenotype (SASP)
  • Regulation of APC/C activators between G1/S and early anaphase
  • S Phase
  • APC/C-mediated degradation of cell cycle proteins
  • Cell Cycle, Mitotic
  • Orc1 removal from chromatin
  • SCF(Skp2)-mediated degradation of p27/p21
  • Regulation of mitotic cell cycle
  • Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
  • APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Mitotic G2-G2/M phases
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Cellular Senescence
  • p53-Dependent G1/S DNA damage checkpoint
  • Cyclin E associated events during G1/S transition
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • G1/S Transition
  • Removal of licensing factors from origins
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • Signaling by PDGF
  • DAP12 interactions
  • DNA Damage/Telomere Stress Induced Senescence
  • GAB1 signalosome
  • Senescence-Associated Secretory Phenotype (SASP)
  • S Phase
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • SCF(Skp2)-mediated degradation of p27/p21
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Adaptive Immune System
  • PIP3 activates AKT signaling
  • Orc1 removal from chromatin
  • p53-Dependent G1 DNA Damage Response
  • PI3K events in ERBB2 signaling
  • Transcriptional activation of p53 responsive genes
  • Downstream signaling of activated FGFR
  • G1/S DNA Damage Checkpoints
  • Innate Immune System
  • Transcriptional activation of cell cycle inhibitor p21
  • Signalling by NGF
  • Synthesis of DNA
  • G1 Phase
  • Regulation of DNA replication
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell Cycle, Mitotic
  • Signaling by FGFR
  • Orc1 removal from chromatin
  • Cyclin D associated events in G1
  • Cell Cycle Checkpoints
CCNB1 and CDKN1A cyclin B1 cyclin-dependent kinase inhibitor 1A (p21, Cip1)
  • Phosphorylation of the APC/C
  • MASTL Facilitates Mitotic Progression
  • Mitotic Prometaphase
  • G2/M Checkpoints
  • Mitotic Prophase
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Activation of NIMA Kinases NEK9, NEK6, NEK7
  • Nuclear Envelope Breakdown
  • G2/M Transition
  • Phosphorylation of Emi1
  • Recruitment of NuMA to mitotic centrosomes
  • Regulation of PLK1 Activity at G2/M Transition
  • M Phase
  • Cyclin A/B1 associated events during G2/M transition
  • G1/S Transition
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • Mitotic G1-G1/S phases
  • Recruitment of mitotic centrosome proteins and complexes
  • G2/M DNA replication checkpoint
  • Condensation of Prometaphase Chromosomes
  • E2F mediated regulation of DNA replication
  • G2/M DNA damage checkpoint
  • Depolymerisation of the Nuclear Lamina
  • Nuclear Pore Complex (NPC) Disassembly
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Regulation of APC/C activators between G1/S and early anaphase
  • APC/C-mediated degradation of cell cycle proteins
  • Cell Cycle, Mitotic
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Resolution of Sister Chromatid Cohesion
  • E2F-enabled inhibition of pre-replication complex formation
  • Regulation of mitotic cell cycle
  • Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
  • Cell Cycle Checkpoints
  • Centrosome maturation
  • Condensation of Prophase Chromosomes
  • Mitotic G2-G2/M phases
  • Polo-like kinase mediated events
  • Signaling by the B Cell Receptor (BCR)
  • Signaling by FGFR in disease
  • Cellular Senescence
  • p53-Dependent G1/S DNA damage checkpoint
  • Cyclin E associated events during G1/S transition
  • AKT phosphorylates targets in the cytosol
  • Signaling by EGFRvIII in Cancer
  • Signaling by SCF-KIT
  • Downstream signaling events of B Cell Receptor (BCR)
  • DAP12 signaling
  • PI3K/AKT activation
  • PI-3K cascade
  • G1/S Transition
  • Removal of licensing factors from origins
  • Switching of origins to a post-replicative state
  • Mitotic G1-G1/S phases
  • Signaling by PDGF
  • DAP12 interactions
  • DNA Damage/Telomere Stress Induced Senescence
  • GAB1 signalosome
  • Senescence-Associated Secretory Phenotype (SASP)
  • S Phase
  • Signaling by ERBB4
  • Constitutive PI3K/AKT Signaling in Cancer
  • Role of LAT2/NTAL/LAB on calcium mobilization
  • PI3K events in ERBB4 signaling
  • Signaling by ERBB2
  • Signaling by EGFR
  • SCF(Skp2)-mediated degradation of p27/p21
  • Downstream signal transduction
  • Signaling by EGFR in Cancer
  • Fc epsilon receptor (FCERI) signaling
  • PI3K/AKT Signaling in Cancer
  • Cyclin A:Cdk2-associated events at S phase entry
  • SCF(Skp2)-mediated degradation of p27/p21
  • Adaptive Immune System
  • PIP3 activates AKT signaling
  • Orc1 removal from chromatin
  • p53-Dependent G1 DNA Damage Response
  • PI3K events in ERBB2 signaling
  • Transcriptional activation of p53 responsive genes
  • Downstream signaling of activated FGFR
  • G1/S DNA Damage Checkpoints
  • Innate Immune System
  • Transcriptional activation of cell cycle inhibitor p21
  • Signalling by NGF
  • Synthesis of DNA
  • G1 Phase
  • Regulation of DNA replication
  • Signaling by Ligand-Responsive EGFR Variants in Cancer
  • NGF signalling via TRKA from the plasma membrane
  • Signaling by Overexpressed Wild-Type EGFR in Cancer
  • Cell Cycle, Mitotic
  • Signaling by FGFR
  • Orc1 removal from chromatin
  • Cyclin D associated events in G1
  • Cell Cycle Checkpoints
CCNB1 and TGFBR2 cyclin B1 transforming growth factor, beta receptor II (70/80kDa)
  • Phosphorylation of the APC/C
  • MASTL Facilitates Mitotic Progression
  • Mitotic Prometaphase
  • G2/M Checkpoints
  • Mitotic Prophase
  • Golgi Cisternae Pericentriolar Stack Reorganization
  • Activation of NIMA Kinases NEK9, NEK6, NEK7
  • Nuclear Envelope Breakdown
  • G2/M Transition
  • Phosphorylation of Emi1
  • Recruitment of NuMA to mitotic centrosomes
  • Regulation of PLK1 Activity at G2/M Transition
  • M Phase
  • Cyclin A/B1 associated events during G2/M transition
  • G1/S Transition
  • Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex
  • Mitotic G1-G1/S phases
  • Recruitment of mitotic centrosome proteins and complexes
  • G2/M DNA replication checkpoint
  • Condensation of Prometaphase Chromosomes
  • E2F mediated regulation of DNA replication
  • G2/M DNA damage checkpoint
  • Depolymerisation of the Nuclear Lamina
  • Nuclear Pore Complex (NPC) Disassembly
  • APC/C:Cdc20 mediated degradation of mitotic proteins
  • Regulation of APC/C activators between G1/S and early anaphase
  • APC/C-mediated degradation of cell cycle proteins
  • Cell Cycle, Mitotic
  • APC/C:Cdc20 mediated degradation of Cyclin B
  • Resolution of Sister Chromatid Cohesion
  • E2F-enabled inhibition of pre-replication complex formation
  • Regulation of mitotic cell cycle
  • Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins
  • Cell Cycle Checkpoints
  • Centrosome maturation
  • Condensation of Prophase Chromosomes
  • Mitotic G2-G2/M phases
  • Polo-like kinase mediated events
  • Loss of Function of TGFBR2 in Cancer
  • TGFBR2 MSI Frameshift Mutants in Cancer
  • TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)
  • SMAD2/3 Phosphorylation Motif Mutants in Cancer
  • Loss of Function of SMAD2/3 in Cancer
  • TGFBR2 Kinase Domain Mutants in Cancer
  • Downregulation of TGF-beta receptor signaling
  • SMAD2/3 MH2 Domain Mutants in Cancer
  • Loss of Function of SMAD4 in Cancer
  • TGFBR1 KD Mutants in Cancer
  • TGF-beta receptor signaling activates SMADs
  • TGFBR1 LBD Mutants in Cancer
  • Loss of Function of TGFBR1 in Cancer
  • Signaling by TGF-beta Receptor Complex in Cancer
  • Signaling by TGF-beta Receptor Complex
  • SMAD4 MH2 Domain Mutants in Cancer
  • Glycerol

Page 21 out of 1171 pages